Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Retained Earnings: 2020-2024

Historic Retained Earnings for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to -$210.8 million.

  • Oncology Institute's Retained Earnings fell 3353.72% to -$263.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$263.9 million, marking a year-over-year decrease of 3353.72%. This contributed to the annual value of -$210.8 million for FY2024, which is 4424.43% down from last year.
  • As of FY2024, Oncology Institute's Retained Earnings stood at -$210.8 million, which was down 4424.43% from -$146.2 million recorded in FY2023.
  • Over the past 5 years, Oncology Institute's Retained Earnings peaked at -$52.3 million during FY2020, and registered a low of -$210.8 million during FY2024.
  • Its 5-year average for Retained Earnings is -$107.1 million, with a median of -$63.2 million in 2021.
  • As far as peak fluctuations go, Oncology Institute's Retained Earnings increased by 24.04% in 2022, and later tumbled by 13168.26% in 2023.
  • Oncology Institute's Retained Earnings (Annual) stood at -$52.3 million in 2020, then dropped by 20.89% to -$63.2 million in 2021, then grew by 0.24% to -$63.1 million in 2022, then tumbled by 131.68% to -$146.2 million in 2023, then crashed by 44.24% to -$210.8 million in 2024.
  • Its Retained Earnings stands at -$210.8 million for FY2024, versus -$146.2 million for FY2023 and -$63.1 million for FY2022.